Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia

Brain Research

Volumn 974, Issue 1-2, 2003, Pages 254-257

  Neilan, Claire L ^a   King, Michael A ^a   Rossi, Grace ^b   Ansonoff, Michael ^c   Pintar, John E ^c   Schiller, Peter W ^d   Pasternak, Gavril W ^a,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e Department of Neurology ^*  (United States)

Author keywords

Analgesia; Knockout; MOR 1; Morphine; Opioid peptide; Strain; Opioid receptor

Indexed keywords

MORPHINE; TYROSYL DEXTRO ARGINYLPHENYLALANYLLYSINAMIDE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0037547066     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02590-3     Document Type: Article

References (37)

1. Abbadie C., Pan Y.-X., Drake C.T., Pasternak G.W. Comparative immunohistochemical distributions of carboxy terminus epitopes from the μ-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat central nervous systems. Neuroscience. 100:2000;141-153.
2. Abbadie C., Pan Y.-X., Pasternak G.W. Differential distribution in rat brain of μ-opioid receptor carboxy terminal splice variants MOR-1C and MOR-1-like immunoreactivity: Evidence for region-specific processing. J. Comp. Neurol. 419:2000;244-256.
3. Abbadie C., Pasternak G.W., Aicher S.A. Presynaptic localization of the carboxy-terminus epitopes of the μ-opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord. Neuroscience. 106:2001;833-842.
4. Bare L.A., Mansson E., Yang D. Expression of two variants of the human μ-opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 354:1994;213-216.
5. Baron A., Shuster L., Elefterhiou B.E., Bailey D.W. Opiate receptors in mice: genetic differences. Life Sci. 17:1975;633-640.
6. Bergeson S.E., Helms M.L., O'Toole L.A., Jarvis M.W., Hain H.S., Mogil J.S., Belknap J.K. Quantitative trait loci influencing morphine antinociception in four mapping populations. Mamm. Genome. 12:2001;546-553.
7. Chang A., Emmel D.W., Rossi G.C., Pasternak G.W. Methadone analgesia in morphine-insensitive CXBK mice. Eur. J. Pharmacol. 351:1998;189-191.
8. 2 receptors in supraspinal antinociception. Life Sci. 54:1994;369-374.
9. Flores C.M., Mogil J.S. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics. 2:2001;177-194.
10. Ikeda K., Ichikawa T., Kobayashi T., Kumanishi T., Oike S., Yano R. Unique behavioural phenotypes of recombinant-inbred CXBK mice: partial deficiency of sensitivity to μ-and κ-agonists. Neurosci. Res. 34:1999;149-155.
11. Lariviere W.R., Chesler E.J., Mogil J.S. Transgenic studies of pain and analgesia: mutation or background genotype? J. Pharmacol. Exp. Ther. 297:2001;467-473.
12. Lariviere W.R., Wilson S.G., Laughlin T.M., Kokayeff A., West E.E., Adhikari S.M., Wan Y., Mogil J.S. Heritability of nociception. III. Genetic relationships among commonly used assays of nociception and hypersensitivity. Pain. 97:2002;75-86.
13. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
14. 2-opioid receptors. Pain. 70:1997;267-277.
15. Mogil J.S., Yu L., Basbaum A.I. Pain genes?: natural variation and transgenic mutants. Annu. Rev. Neurosci. 23:2000;777-811.
16. 1]DALDA, a highly potent and selective μ-opioid peptide. Eur. J. Pharmacol. 419:2001;15-23.
17. Pan Y.-X., Xu J., Mahurter L., Bolan E.A., Xu M.M., Pasternak G.W. Generation of the μ-opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc. Natl. Acad. Sci. USA. 98:2001;14084-14089.
18. Pan Y.-X., Xu J., Rossi G.C., Leventhal L., Wan B.-L., Zuckerman A., Pasternak G.W. Cloning and expression of a novel splice variant of the mouse μ-opioid receptor (MOR-1) gene. Soc. Neurosci. 24:1998;524.
19. Pan Y.X., Xu J., Bolan E.A., Abbadie C., Chang A., Zuckerman A., Rossi G.C., Pasternak G.W. Identification and characterization of three new alternatively spliced μ-opioid receptor isoforms. Mol. Pharmacol. 56:1999;396-403.
20. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16:1993;1-18.
21. Pasternak G.W. Incomplete cross tolerance and multiple μ-opioid peptide receptors. Trends Pharmacol. Sci. 22:2001;67-70.
22. Pasternak G.W., Pan Y.-X. Antisense mapping: Assessing the functional significance of genes and splice variants. Methods Enzymol. 314:2000;51-60.
23. Pasternak G.W., Standifer K.M. Mapping of opioid receptors using antisense oligodeoxynucleotides: Correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16:1995;344-350.
24. Pick C.G., Cheng J., Paul D., Pasternak G.W. Genetic influences in opioid analgesic sensitivity in mice. Brain Res. 556:1991;295-298.
25. Pick C.G., Nejat R., Pasternak G.W. Independent expression of two pharmacologically distinct supraspinal μ analgesic systems in genetically different mouse strains. J. Pharmacol. Exp. Ther. 2265:1993;166-171.
26. Reith M.E.A., Sershen H., Vadasz C., Lajtha A. Strain differences in opiate receptors in mouse brain. Eur. J. Pharmacol. 74:1981;377-380.
27. Riba P., Ben Y., Nguyen T.M., Furst S., Schiller P.W., Lee N.M. [Dmt(1)]DALDA is highly selective and potent at μ-opioid receptors, but is not cross-tolerant with systemic morphine 1. Curr. Med. Chem. 9:2002;31-39.
28. Rossi G.C., Brown G.P., Leventhal L., Yang K., Pasternak G.W. Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci. Lett. 216:1996;1-4.
29. Rossi G.C., Pan Y.-X., Brown G.P., Pasternak G.W. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6β-glucuronide receptor. FEBS Lett. 369:1995;192-196.
30. Schiller P.W., Nguyen T.M.D., Berezowska I., Dupuis S. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 35:2000;895-901.
31. Schuller A.G., King M.A., Zhang J., Bolan E., Pan Y.X., Morgan D.J., Chang A., Czick M.E., Unterwald E.M., Pasternak G.W., Pintar J.E. Retention of heroin and morphine-6 β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2:1999;151-156.
32. 2 (DALDA) and [Dmt1] DALDA. J. Pharmacol. Exp. Ther. 297:2001;364-371.
33. Szeto H.H., Lovelace J.L., Fridland G., Soong Y., Fasolo J., Wu D., Desiderio D.M., Schiller P.W. In vivo pharmacokinetics of selective μ-opioid peptide agonists 1. J. Pharmacol. Exp. Ther. 298:2001;57-61.
34. Tallarida R.J., Murray R.B. Manual of Pharmacological Calculations with Computer Programs. 1987;Springer, New York.
35. Vaught J.L., Mathiasen J.H.R., Raffa R.B. Examination of the involvement of supraspinal and spinal μ and δ opioid receptors in analgesia using the μ-receptor deficient CXBK mouse. J. Pharmacol. Exp. Ther. 245:1988;12-16.
36. Wolozin B.L., Pasternak G.W. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA. 78:1981;6181-6185.
37. Zimprich A., Simon T., Hollt V. Cloning and expression of an isoform of the rat μ-opioid receptor (rMOR 1 B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 359:1995;142-146.